Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Fig. 2

Forest plot of CGRP mAb vs. placebo for the changes in baseline monthly migraine days. The estimated pooled WMD was − 1.44 (95% CI, − 1.68 to − 1.19) with high statistical significance (P < 0.00001). There was low heterogeneity among the studies (I2 = 6%). SD standard deviation, CI confidence interval, WMD weighted mean difference

Back to article page